Enhanced Palliative Care in MDS and AML
Myelodysplastic Syndromes
About this trial
This is an interventional supportive care trial for Myelodysplastic Syndromes focused on measuring Myelodysplastic syndrome, Acute myeloid leukemia, Palliative care
Eligibility Criteria
Inclusion Criteria:
- Myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) defined using the World Health Organization Classification 2016.
- Patients who are able to read and respond to questions in Chinese.
Exclusion Criteria:
Patients who are already receiving care from a palliative care unit will be excluded. Patients who require immediate palliative care service, e.g. end-of-life care, will be excluded and receive palliative care immediately.
Sites / Locations
- Department of Medicine, the University of Hong Kong, Queen Mary Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Enhanced Haematology Palliative Care ("Fast-track") Group
Conventional Supportive Care Group
Patients who are assigned to enhanced haematology palliative care ("fast-track" group) will be seen, within 2 days of enrollment, at the out-patient clinic or in-patient setting by the haematology palliative care team that comprises a palliative medicine specialist or a haematologist with palliative care experience, a full-time palliative care nurse, and a medical social worker concentrating on haematology palliative patients.
Patients who are assigned to the conventional supportive care group will be under care of haematologists and nurse specialists in haematology After 12 weeks of conventional supportive care, patients randomized to this group will receive services from the palliative care team and assessed every two weeks same the "fast-track" group